Tags

Type your tag names separated by a space and hit enter

Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication.
Br J Cancer. 2020 Jul 07 [Online ahead of print]BJ

Abstract

BACKGROUND

Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers.

METHODS

We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis.

RESULTS

We included 261,745 patients with a first primary cancer, of whom 55% had at least one comorbid condition at diagnosis and 27% had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications.

CONCLUSION

Among patients with a newly established cancer diagnosis, 55% had at least one comorbid condition and 32% were exposed to polypharmacy.

Authors+Show Affiliations

Late Effect Research Unit CASTLE, Department of Oncology, Rigshospitalet, Blegdamsvej 58, 9601, 2100, Copenhagen, Denmark. Katrine.bjerre.loeppenthin@regionh.dk. Psychological Aspects of Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. Katrine.bjerre.loeppenthin@regionh.dk.Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark.Late Effect Research Unit CASTLE, Department of Oncology, Rigshospitalet, Blegdamsvej 58, 9601, 2100, Copenhagen, Denmark. Psychological Aspects of Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Statistics and Data Analysis, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Bispebjerg Bakke 24, 2400, Copenhagen, Denmark.Psychological Aspects of Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Research Center for Multimorbidity and Chronic Conditions, Region Zealand, University of Copenhagen, Copenhagen, Denmark.Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.Psychological Aspects of Cancer, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32632149

Citation

Loeppenthin, Katrine, et al. "Total Burden of Disease in Cancer Patients at Diagnosis-a Danish Nationwide Study of Multimorbidity and Redeemed Medication." British Journal of Cancer, 2020.
Loeppenthin K, Dalton SO, Johansen C, et al. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. Br J Cancer. 2020.
Loeppenthin, K., Dalton, S. O., Johansen, C., Andersen, E., Christensen, M. B., Pappot, H., Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, U., Ørsted, J., & Bidstrup, P. E. (2020). Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. British Journal of Cancer. https://doi.org/10.1038/s41416-020-0950-3
Loeppenthin K, et al. Total Burden of Disease in Cancer Patients at Diagnosis-a Danish Nationwide Study of Multimorbidity and Redeemed Medication. Br J Cancer. 2020 Jul 7; PubMed PMID: 32632149.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. AU - Loeppenthin,Katrine, AU - Dalton,Susanne Oksbjerg, AU - Johansen,Christoffer, AU - Andersen,Elisabeth, AU - Christensen,Mikkel Bring, AU - Pappot,Helle, AU - Petersen,Lone Nørgaard, AU - Thisted,Lise Bjerrum, AU - Frølich,Anne, AU - Mortensen,Christiane Ehlers, AU - Lassen,Ulrik, AU - Ørsted,Jytte, AU - Bidstrup,Pernille Envold, Y1 - 2020/07/07/ PY - 2019/11/14/received PY - 2020/06/04/accepted PY - 2020/05/19/revised PY - 2020/7/8/entrez JF - British journal of cancer JO - Br. J. Cancer N2 - BACKGROUND: Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers. METHODS: We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis. RESULTS: We included 261,745 patients with a first primary cancer, of whom 55% had at least one comorbid condition at diagnosis and 27% had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications. CONCLUSION: Among patients with a newly established cancer diagnosis, 55% had at least one comorbid condition and 32% were exposed to polypharmacy. SN - 1532-1827 UR - https://www.unboundmedicine.com/medline/citation/32632149/Total_burden_of_disease_in_cancer_patients_at_diagnosis-a_Danish_nationwide_study_of_multimorbidity_and_redeemed_medication L2 - http://dx.doi.org/10.1038/s41416-020-0950-3 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.